

Medical Policy: Libtayo® (cemiplimab-rwlc)

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.117	February 5, 2024	January 1 st , 2019

Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Libtayo® (Cemiplimab-rwlc) is a recombinant human IgG4 monoclonal antibody that binds to human programmed death receptor-1 (PD-1) and blocks its interaction with PD-1 ligands 1 and 2 (PD-L1 and PD-L2), which is the interaction responsible for the inhibition of T-cell proliferation and cytokine production, thus releasing the PD-1 pathway-mediated inhibition of immune response, including anti-tumor response.

Libtayo (cemiplimab-rwlc) is FDA approved for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Length of Authorization

Coverage will be provided for 6 months and may be renewed.

Neoadjuvant therapy in Cutaneous Squamous Cell Carcinoma (cSCC) can be authorized up to a maximum of 4 doses and cannot be renewed.

Dosing Limits [Medical Benefit]

Single dose limit 350 mg (350 billable units (350 mg) every 21 days)

Guideline

I. Initial Approval Criteria

Libtayo may be considered medically necessary if the below condition is met **AND** use is consistent with the medical necessity criteria that follows:

1. Cutaneous Squamous Cell Carcinoma (CSCC)

A. Patient must be ≥ 18 years of age; **AND**

i. The patient has unresectable locally advanced or metastatic CSCC AND is not a candidate for curative surgery or curative radiation **OR**

ii. Patient has very-high risk, locally advanced, unresectable, or regional disease AND Medication will be used as neoadjuvant therapy; **AND**

B. Libtayo is being used as a single agent

2. Basal Cell carcinoma (BCC)

A. Patient must have locally advanced or metastatic basal cell carcinoma (laBCC or mBCC); **AND**

B. Patient must have been previously treated with a hedgehog pathway inhibitor (e.g., vismodegib, sonidegib, etc) **OR** for whom a hedgehog pathway inhibitor is not appropriate.

3. Non-Small Cell Lung Cancer (NSCLC)

A. Patient has non-small cell lung cancer with no EGFR, ALK, or ROS1 aberrations; **AND**

B. Patient must have locally advanced disease where patients are not candidates for surgical resection or definitive chemoradiation **OR** metastatic disease; **AND**

i. Medication is being used in combination with platinum-based chemotherapy for the first-line treatment; **OR**

ii. Medication is being used as a single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) $\geq 50\%$] as determined by an FDA-approved test

Limitations/Exclusions

1. Libtayo (cemiplimab-rwlc) is not considered medically necessary when any of the following selection criteria are met:

A. Libtayo (cemiplimab-rwlc) is being used after disease progression with the same regimen or prior treatment with a PD-1/PDL-1/BRAF inhibitor.

B. Concurrent use or within 4 weeks prior to first dose of Libtayo (cemiplimab-rwlc) with other immunomodulating agents (e.g., immunosuppressive corticosteroid doses, therapeutic vaccines, cytokine

treatments, or agents that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), 4-1BB (CD137), or OX-40, etc.)

- C. Significant autoimmune disease that required treatment with systemic immunosuppressive treatments, active infection, history of pneumonitis or solid organ transplant.
- D. Dosing exceeds single dose limit of Libtayo (cemiplimab-rwlc) 350 mg.
- E. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature may be deemed as not approvable and therefore not reimbursable.

II. Renewal Criteria

1. Patient continues to meet the criteria in the INITIAL APPROVAL CRITERIA; **AND**
2. Patient does not experience unacceptable toxicity from this drug. Examples of unacceptable toxicity include the following: severe infusion reactions, severe immune-mediated adverse reactions such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis/renal dysfunction, rash, encephalitis, etc.; **AND**
3. Tumor response with stabilization of disease or decrease in size of tumor or tumor spread has been demonstrated.

Dosage/Administration

Indication	Dose
All Indications	350 mg IV infusion every 3 weeks until disease progression or unacceptable toxicity (Neoadjuvant therapy in Cutaneous Squamous Cell Carcinoma (cSCC) can be authorized up to a maximum of 4 doses and cannot be renewed.)

Applicable Procedure Codes

Code	Description
J9119	Effective 10/1/19, Injection, cemiplimab-rwlc, 1 mg

Applicable NDCs

Code	Description
61755-0008-xx	Libtayo 350 mg/7 ml single use vial

ICD-10 Diagnoses

Code	Description
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung

C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C44.01	Basal cell carcinoma of skin of lip
C44.02	Squamous cell carcinoma of skin of lip
C44.111	Basal cell carcinoma of skin of unspecified eyelid, including canthus
C44.121	Squamous cell carcinoma of skin of unspecified eyelid, including canthusb
C44.1221	Squamous cell carcinoma of skin of right upper eyelid, including canthus
C44.1222	Squamous cell carcinoma of skin of right lower eyelid, including canthus
C44.1291	Squamous cell carcinoma of skin of left upper eyelid, including canthus
C44.1292	Squamous cell carcinoma of skin of left lower eyelid, including canthus
C44.211	Basal cell carcinoma of skin of unspecified ear and external auricular canal
C44.212	Basal cell carcinoma of skin of right ear and external auricular canal
C44.219	Basal cell carcinoma of skin of left ear and external auricular canal
C44.221	Squamous cell carcinoma of skin of unspecified ear and external auricular canalb
C44.222	Squamous cell carcinoma of skin of right ear and external auricular canal
C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal
C44.310	Basal cell carcinoma of skin of unspecified parts of face
C44.311	Basal cell carcinoma of skin of nose
C44.319	Basal cell carcinoma of skin of other parts of face
C44.320	Squamous cell carcinoma of skin of unspecified parts of faceb
C44.321	Squamous cell carcinoma of skin of nose
C44.329	Squamous cell carcinoma of skin of other parts of face
C44.41	Basal cell carcinoma of skin of scalp and neck
C44.42	Squamous cell carcinoma of skin of scalp and neck
C44.510	Basal cell carcinoma of anal skin
C44.511	Basal cell carcinoma of skin of breast
C44.519	Basal cell carcinoma of skin of other part of trunk
C44.520	Squamous cell carcinoma of anal skin
C44.521	Squamous cell carcinoma of skin of breast
C44.529	Squamous cell carcinoma of skin of other part of trunk
C44.611	Basal cell carcinoma of skin of unspecified upper limb, including shoulder
C44.612	Basal cell carcinoma of skin of right upper limb, including shoulder
C44.619	Basal cell carcinoma of skin of left upper limb, including shoulder
C44.621	Squamous cell carcinoma of skin of unspecified upper limb, including shoulderb
C44.622	Squamous cell carcinoma of skin of right upper limb, including shoulder
C44.629	Squamous cell carcinoma of skin of left upper limb, including shoulder
C44.711	Basal cell carcinoma of skin of unspecified lower limb, including hip
C44.712	Basal cell carcinoma of skin of right lower limb, including hip
C44.719	Basal cell carcinoma of skin of left lower limb, including hip
C44.721	Squamous cell carcinoma of skin of unspecified lower limb, including hip
C44.722	Squamous cell carcinoma of skin of right lower limb, including hip
C44.729	Squamous cell carcinoma of skin of left lower limb, including hip

C44.81	Basal cell carcinoma of overlapping sites of skin
C44.82	Squamous cell carcinoma of skin of left lower limb, including hip
C44.91	Basal cell carcinoma of skin, unspecified
C44.92	Squamous cell carcinoma of overlapping sites of skin
Z85.118	Personal history of other malignant neoplasm of bronchus and lung

Revision History

Company(ies)	DATE	REVISION																						
EmblemHealth & ConnectiCare	2/5/2024	<p>Annual Review: Removed NDC: 61755-0007-xx, Updated length of authorization, dosing limits and dosing chart.</p> <p>Initial Criteria: Cutaneous Squamous Cell Carcinoma (CSCC)</p> <p>Removed: "Cutaneous squamous cell carcinoma with nodal or distant metastatic disease; AND" Added: "Patient has very-high risk, locally advanced, unresectable, or regional disease AND Medication will be used as neoadjuvant therapy; AND"</p>																						
EmblemHealth & ConnectiCare	06/08/2023	<p>Annual Review: Added Basal Cell Carcinoma indication and Non-Small Cell Lung Cancer Indication</p> <p><u>Cutaneous Squamous Cell Carcinoma: Initial Criteria- Removed:</u></p> <p>"a. Patient has not received previous therapy with the following:</p> <p>i. A programmed death (PD-1/PD-L1)-directed therapy (e.g., avelumab, pembrolizumab, atezolizumab, durvalumab, nivolumab, etc.) unless otherwise specified; OR</p> <p>ii. A cytotoxic T-lymphocyte antigen 4 (CTLA-4) targeting agent (e.g., ipilimumab, etc.) within the previous 4 weeks prior to therapy; OR</p> <p>iii. A BRAF-inhibitor (e.g., vemurafenib, dabrafenib, encorafenib, etc.); OR</p> <p>iv. A small-molecule inhibitor (phosphatidylinositol-3 kinase inhibitor [PI3-K]) therapy (e.g., idelalisib, duvelisib, etc.)" Added "Libtayo is being used as a single agent"</p> <p>Added codes:</p> <table border="1"> <tr> <td>C33</td> <td>Malignant neoplasm of trachea</td> </tr> <tr> <td>C34.00</td> <td>Malignant neoplasm of unspecified main bronchus</td> </tr> <tr> <td>C34.01</td> <td>Malignant neoplasm of right main bronchus</td> </tr> <tr> <td>C34.02</td> <td>Malignant neoplasm of left main bronchus</td> </tr> <tr> <td>C34.10</td> <td>Malignant neoplasm of upper lobe, unspecified bronchus or lung</td> </tr> <tr> <td>C34.11</td> <td>Malignant neoplasm of upper lobe, right bronchus or lung</td> </tr> <tr> <td>C34.12</td> <td>Malignant neoplasm of upper lobe, left bronchus or lung</td> </tr> <tr> <td>C34.2</td> <td>Malignant neoplasm of middle lobe, bronchus or lung</td> </tr> <tr> <td>C34.30</td> <td>Malignant neoplasm of lower lobe, unspecified bronchus or lung</td> </tr> <tr> <td>C34.31</td> <td>Malignant neoplasm of lower lobe, right bronchus or lung</td> </tr> <tr> <td>C34.32</td> <td>Malignant neoplasm of lower lobe, left bronchus or</td> </tr> </table>	C33	Malignant neoplasm of trachea	C34.00	Malignant neoplasm of unspecified main bronchus	C34.01	Malignant neoplasm of right main bronchus	C34.02	Malignant neoplasm of left main bronchus	C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	C34.2	Malignant neoplasm of middle lobe, bronchus or lung	C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	C34.32	Malignant neoplasm of lower lobe, left bronchus or
C33	Malignant neoplasm of trachea																							
C34.00	Malignant neoplasm of unspecified main bronchus																							
C34.01	Malignant neoplasm of right main bronchus																							
C34.02	Malignant neoplasm of left main bronchus																							
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung																							
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung																							
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung																							
C34.2	Malignant neoplasm of middle lobe, bronchus or lung																							
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung																							
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung																							
C34.32	Malignant neoplasm of lower lobe, left bronchus or																							

		lung
		C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung
		C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung
		C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung
		C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung
		C34.91 Malignant neoplasm of unspecified part of right bronchus or lung
		C34.92 Malignant neoplasm of unspecified part of left bronchus or lung
		C44.01 Basal cell carcinoma of skin of lip
		C44.111 Basal cell carcinoma of skin of unspecified eyelid, including canthus
		C44.211 Basal cell carcinoma of skin of unspecified ear and external auricular canal
		C44.212 Basal cell carcinoma of skin of right ear and external auricular canal
		C44.219 Basal cell carcinoma of skin of left ear and external auricular canal
		C44.41 Basal cell carcinoma of skin of scalp and neck
		C44.510 Basal cell carcinoma of anal skin
		C44.511 Basal cell carcinoma of skin of breast
		C44.519 Basal cell carcinoma of skin of other part of trunk
		C44.510 Basal cell carcinoma of anal skin
		C44.511 Basal cell carcinoma of skin of breast
		C44.519 Basal cell carcinoma of skin of other part of trunk
		C44.611 Basal cell carcinoma of skin of unspecified upper limb, including shoulder
		C44.612 Basal cell carcinoma of skin of right upper limb, including shoulder
		C44.619 Basal cell carcinoma of skin of left upper limb, including shoulder
		C44.711 Basal cell carcinoma of skin of unspecified lower limb, including hip
		C44.712 Basal cell carcinoma of skin of right lower limb, including hip
		C44.719 Basal cell carcinoma of skin of left lower limb, including hip
		C44.81 Basal cell carcinoma of overlapping sites of skin
		C44.91 Basal cell carcinoma of skin, unspecified
		Z85.118 Personal history of other malignant neoplasm of bronchus and lung
		Removed code: Z85.828
EmblemHealth & ConnectiCare	1/10/2023	Transferred to new template
EmblemHealth & ConnectiCare	7/7/2021	Removed C Code

EmblemHealth & ConnectiCare	8/15/2019	Removed J9999, Added New Code J9119, effective 10/1/19
EmblemHealth & ConnectiCare	3/29/2019	Added New Code C9044

References

1. Libtayo (cemiplimab-rwlc) PI prescribing information. Regeneron Pharmaceuticals, Inc. Tarrytown, NY. Revised November, 2020.
2. Clinical Pharmacology Elsevier Gold Standard. 2020.
3. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2018.
4. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium. 2020.
5. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD. 2018.